Company intelligence / Profile preview

RenalGuard Solutions

Milford, Massachusetts, United States

Ownership: Private
Employees: ~27
Development stage: Other

Overview

RenalGuard Therapy has demonstrated efficacy in multiple investigator-sponsored and pivotal studies, showing significant reduction in the incidence of contrast-induced nephropathy and peri-procedural acute kidney injury in patients undergoing cardiac and vascular procedures. The therapy is CE-marked and available commercially in Europe and select markets, with U.S. pivotal trials ongoing to support FDA premarket approval filings. Peer-reviewed publications and meta-analyses confirm benefits over standard of care, reducing incidence of AKI, dialysis needs, adverse events, and mortality in at-risk populations.[1][2][3]

Therapeutic areas: NephrologyCardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on RenalGuard Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RenalGuard Solutions.

Explore the full profile